IDEAS home Printed from https://ideas.repec.org/a/wly/hlthec/v34y2025i8p1396-1409.html

The Effects of Medical and Recreational Cannabis Laws on Prescription Drug Claims in Commercial Group Insurance Markets

Author

Listed:
  • Amanda C. Cook
  • E. Tice Sirmans
  • Rhet A. Smith

Abstract

Initially introduced as an alternative medical treatment, cannabis has been conditionally legalized in most U.S. states. Using prescription drug claims as reported by small and large group insurers in the NAIC Supplemental Health Care Exhibit from 2010–2019, we examine the impact of medical and recreational cannabis laws on prescription drug expenditures of working‐age individuals. We use a difference‐in‐differences framework and find significant reductions in prescription drug claims per enrollee of $34–42 annually in the small group insurance market following recreational cannabis legalization. While we do not observe similar reductions in claims in large group insurance markets, we find weak evidence that the reduced expenditures in small group insurance correspond with reductions in premiums indicating positive spillover effects from recreational cannabis for insured enrollees of small group insurance plans.

Suggested Citation

  • Amanda C. Cook & E. Tice Sirmans & Rhet A. Smith, 2025. "The Effects of Medical and Recreational Cannabis Laws on Prescription Drug Claims in Commercial Group Insurance Markets," Health Economics, John Wiley & Sons, Ltd., vol. 34(8), pages 1396-1409, August.
    • Handle: RePEc:wly:hlthec:v:34:y:2025:i:8:p:1396-1409
    DOI: 10.1002/hec.4967
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/hec.4967
    Download Restriction: no
    File URL: https://libkey.io/10.1002/hec.4967?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Cameron M. Ellis & Martin F. Grace & Rhet A. Smith & Juan Zhang, 2022. "Medical cannabis and automobile accidents: Evidence from auto insurance," Health Economics, John Wiley & Sons, Ltd., vol. 31(9), pages 1878-1897, September.
    2. D. Mark Anderson & Daniel I. Rees, 2023. "The Public Health Effects of Legalizing Marijuana," Journal of Economic Literature, American Economic Association, vol. 61(1), pages 86-143, March.
    3. Rahi Abouk & Keshar M. Ghimire & Johanna Catherine Maclean & David Powell, 2023. "Pain Management and Work Capacity: Evidence From Workers’ Compensation and Marijuana Legalization," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 42(3), pages 737-770, June.
    4. Angélica Meinhofer, 2018. "Prescription Drug Monitoring Programs: The Role of Asymmetric Information on Drug Availability and Abuse," American Journal of Health Economics, University of Chicago Press, vol. 4(4), pages 504-526, Fall.
    5. Rosalie L. Pacula & David Powell & Paul Heaton & Eric L. Sevigny, 2015. "Assessing the Effects of Medical Marijuana Laws on Marijuana Use: The Devil is in the Details," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 34(1), pages 7-31, January.
    6. Shyam Raman & Ashley C. Bradford, 2022. "Recreational cannabis legalizations associated with reductions in prescription drug utilization among Medicaid enrollees," Health Economics, John Wiley & Sons, Ltd., vol. 31(7), pages 1513-1521, July.
    7. Meinhofer, Angélica & Witman, Allison E. & Hinde, Jesse M. & Simon, Kosali, 2021. "Marijuana liberalization policies and perinatal health," Journal of Health Economics, Elsevier, vol. 80(C).
    8. Sun, Liyang & Abraham, Sarah, 2021. "Estimating dynamic treatment effects in event studies with heterogeneous treatment effects," Journal of Econometrics, Elsevier, vol. 225(2), pages 175-199.
    9. Jiebing Wen & Hefei Wen & J. S. Butler & Jeffery C. Talbert, 2021. "The impact of medical and recreational marijuana laws on opioid prescribing in employer‐sponsored health insurance," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 989-1000, May.
    10. Alex Hollingsworth & Coady Wing & Ashley C. Bradford, 2022. "Comparative Effects of Recreational and Medical Marijuana Laws on Drug Use among Adults and Adolescents," Journal of Law and Economics, University of Chicago Press, vol. 65(3), pages 515-554.
    11. Ashley C. Bradford & W. David Bradford, 2018. "The Impact of Medical Cannabis Legalization on Prescription Medication Use and Costs under Medicare Part D," Journal of Law and Economics, University of Chicago Press, vol. 61(3), pages 461-487.
    12. Thomas C. Buchmueller & Colleen Carey, 2018. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 77-112, February.
    13. Angélica Meinhofer, 2018. "Prescription Drug Monitoring Programs: The Role of Asymmetric Information on Drug Availability and Abuse," American Journal of Health Economics, MIT Press, vol. 4(4), pages 504-526, Fall.
    14. Anca M. Grecu & Dhaval M. Dave & Henry Saffer, 2019. "Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 38(1), pages 181-209, January.
    15. Callaway, Brantly & Sant’Anna, Pedro H.C., 2021. "Difference-in-Differences with multiple time periods," Journal of Econometrics, Elsevier, vol. 225(2), pages 200-230.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Burton, Anne M. & Churchill, Brandyn F., 2025. "Supply-side opioid restrictions and the retail pharmacy market," Journal of Health Economics, Elsevier, vol. 104(C).
    2. Kaestner, Robert & Ziedan, Engy, 2023. "Effects of prescription opioids on employment, earnings, marriage, disability and mortality: Evidence from state opioid control policies," Labour Economics, Elsevier, vol. 82(C).
    3. Aljoscha Janssen & Xuan Zhang, 2023. "Retail Pharmacies and Drug Diversion during the Opioid Epidemic," American Economic Review, American Economic Association, vol. 113(1), pages 1-33, January.
    4. Simone Balestra & Helge Liebert & Nicole Maestas & Tisamarie B. Sherry, 2021. "Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic," NBER Working Papers 29596, National Bureau of Economic Research, Inc.
    5. Alberto Ortega, 2023. "The highs and the lows: Recreational marijuana laws and mental health treatment," Health Economics, John Wiley & Sons, Ltd., vol. 32(10), pages 2173-2191, October.
    6. Alice M. Ellyson & Jevay Grooms & Alberto Ortega, 2022. "Flipping the script: The effects of opioid prescription monitoring on specialty‐specific provider behavior," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 297-341, February.
    7. Weiwei Chen & Johanna Catherine Maclean & Michael T. French, 2026. "Legalizing Cannabis: Implications for Child Maltreatment," NBER Working Papers 34673, National Bureau of Economic Research, Inc.
    8. Sabia, Joseph J. & Dave, Dhaval & Alotaibi, Fawaz & Rees, Daniel I., 2024. "The effects of recreational marijuana laws on drug use and crime," Journal of Public Economics, Elsevier, vol. 234(C).
    9. Shishir Shakya & Collin Hodges, 2023. "Must‐access prescription drug monitoring programs and retail opioid sales," Contemporary Economic Policy, Western Economic Association International, vol. 41(1), pages 146-165, January.
    10. Borbely, Daniel & Lenhart, Otto & Norris, Jonathan & Romiti, Agnese, 2022. "Marijuana Legalization and Mental Health," IZA Discussion Papers 15729, IZA Network @ LISER.
    11. Kim, Bokyung, 2021. "Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences," Journal of Health Economics, Elsevier, vol. 75(C).
    12. Dhaval Dave & Bilge Erten & David Hummel & Pinar Keskin & Shuo Zhang, 2025. "Fighting abuse with prescription tracking: mandatory drug monitoring and intimate partner violence," Journal of Population Economics, Springer;European Society for Population Economics, vol. 38(3), pages 1-27, September.
    13. Shishir Shakya & Jane E. Ruseski, 2023. "The effect of Prescription Drug Monitoring Programs on county‐level opioid prescribing practices and spillovers," Contemporary Economic Policy, Western Economic Association International, vol. 41(3), pages 435-454, July.
    14. Rahi Abouk & Keshar M. Ghimire & Johanna Catherine Maclean & David Powell, 2023. "Pain Management and Work Capacity: Evidence From Workers’ Compensation and Marijuana Legalization," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 42(3), pages 737-770, June.
    15. Mizushima, Yuji & Powell, David & Abouk, Rahi & Damberg, Cheryl, 2025. "Regulating quasi-legal markets: Evidence from pain management clinic laws," Journal of Public Economics, Elsevier, vol. 252(C).
    16. Meinhofer, Angélica & Witman, Allison E. & Hinde, Jesse M. & Simon, Kosali, 2021. "Marijuana liberalization policies and perinatal health," Journal of Health Economics, Elsevier, vol. 80(C).
    17. Jenny Williams & Rosalie Liccardo Pacula & Rosanna Smart, 2025. "Racial and ethnic differences in quitting when marijuana retail markets are legal: evidence from California," Empirical Economics, Springer, vol. 69(5), pages 2755-2781, November.
    18. Aparna Soni, 2024. "Estimating price elasticities of demand for pain relief drugs: evidence from Medicare Part D," International Journal of Health Economics and Management, Springer, vol. 24(4), pages 481-515, December.
    19. Anderson, D. Mark & Rees, Daniel I., 2021. "The Public Health Effects of Legalizing Marijuana," IZA Discussion Papers 14292, IZA Network @ LISER.
    20. Thomas C. Buchmueller & Colleen M. Carey & Giacomo Meille, 2020. "How well do doctors know their patients? Evidence from a mandatory access prescription drug monitoring program," Health Economics, John Wiley & Sons, Ltd., vol. 29(9), pages 957-974, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:34:y:2025:i:8:p:1396-1409. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.